Abstract
Cognitive impairment in multiple domains is common in patients with schizophrenia and may be a powerful determinant of poor functional ability and quality of life. We report a double-blind, placebo-controlled, cross-over study of donepezil augmentation in a schizoaffective disorder patient stabilized on olanzapine pharmacotherapy. The patient showed significant improvements in several cognitive measures and increased activation of prefrontal cortex and basal ganglia on functional MRI during the donepezil augmentation. In addition, the donepezil augmentation resulted in a reduction of depressive symptoms and in significant improvements in functional abilities and quality of life. Further studies of donepezil augmentation of neuroleptics in schizophrenia are warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 105-110 |
Number of pages | 6 |
Journal | Neurocase |
Volume | 7 |
Issue number | 2 |
DOIs | |
State | Published - 2001 |
Keywords
- Cognition
- Donepezil
- Functional magnetic resonance imaging
- Schizoaffective disorder